With independent pharmacies now facing significant challenges, healthcare SaaS provider Charac was pleased to announce more investment so it can accelerate a digitization drive.
Life sciences investment group and part of global investment firm Carlyle, Abingworth announced last week it had exceeded its $300 million target by $56 million.
Advanced tech company, PhaseV, has raised $15 million in funding that it says it will use to ‘push the boundaries of machine learning for clinical trial optimization’.
Integrated drug formulation and clinical trials company, BDD Pharma, will be expanding its phase appropriate development, manufacturing, and clinical testing services after a £2 million ($1.3 million) investment.
Global Healthcare Opportunities (GHO) Capital Partners LLP along with Partners Group has announced today (May 25) that it has invested an undisclosed amount in GHO portfolio company, Sterling Pharma Solutions.
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
A powerful tool that could capture abdominal aortic aneurysms (AAA) and refer those at risk is the first to be given clearance by the US Food and Drink Administration (FDA).
The funding will be split between 17 US non-profit organizations this year, as the company reveals the broader progress it has made towards its long-term inclusion and diversity goals.
Experic raises $14m in series B led by Harro Hofilger Packaging Systems and East Seattle Partners as CDMO sees growth in DPI product and clinical trial supply needs.
The CRO focuses its services towards biotechs by stating that they are cheaper and more efficient compared to rivals, and it was this principle that drew in General Catalyst to provide investment.
The agency's requested funding for FY 2023, nearly 34% higher than for FY 2022, calls for investments in public health modernization and pandemic preparation.
The company reportedly will utilize the investment funding to expand its research platform, and to advance six of its preclinical therapeutic programs.
ImmunoScape plans to use the investor funds to grow its Asia presence, expand into the US, and to further develop its Deep Immunomics platform technology.
The development technology firm plans to use the funds, sourced from a wide range of investors, to expand its dev-ops platform and expand its global reach.
Immunai has secured a total of $80m in funding to develop and promote its efforts to harness machine learning to fuel advancement of novel immunotherapies.
Cancer Research UK to support the clinical development of Hummingbird’s investigative cancer treatment which has the potential to fight drug resistant tumours.
